- Home
- AUPH vs XXI Comparison
AUPH vs XXI Comparison
Compare AUPH & XXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUPH | XXI |
|---|---|---|
| Founded | 1993 | 2025 |
| Country | Canada | United States |
| Employees | N/A | 3 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUPH | XXI |
|---|---|---|
| Price | $15.34 | $5.02 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 05-07-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | $62.56 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $8.80 | $4.27 |
| 52 Week High | $19.25 | $11.49 |
Technical Indicators
Market Signals| Indicator | AUPH | XXI |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 38.60 |
| Support Level | $14.68 | $4.93 |
| Resistance Level | $16.38 | $5.71 |
| Average True Range (ATR) | 0.63 | 0.31 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 11.69 | 47.76 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.